AVITA Medical’s Cohealyx-I study interim results show a significant acceleration in skin grafting time for full-thickness wounds, reducing mean time to graft from 33.2 to 13.6 days. The ongoing trial’s promising data could reshape wound care protocols.
- Mean time to graft reduced to 13.6 days versus 33.2-day benchmark
- Median grafting time 11 days with some as early as 5 days
- 90% investigator satisfaction reported at grafting stage
- Study ongoing, full data expected in 2026
- Key opinion leader webinar scheduled during American Burn Association meeting
Significant Reduction in Time to Skin Grafting
AVITA Medical (ASX:AVH) has revealed interim data from its Cohealyx-I study indicating a dramatic reduction in the time required to prepare full-thickness wounds for skin grafting. The mean time to grafting dropped to 13.6 days, nearly 20 days faster than the 33.2-day benchmark derived from a meta-analysis of approximately 900 patients treated with leading dermal matrices. The study demonstrated statistical superiority with a p-value below 0.001, underscoring the potential clinical impact of Cohealyx, a collagen-based dermal matrix designed to support vascularization.
The median time to graft was 11 days, with some patients receiving grafts as early as 5 days post-treatment. Notably, 72% of patients were grafted within 14 days, a pace that could significantly improve patient recovery timelines and reduce hospital stays.
Strong Investigator Endorsement and Clinical Adoption Potential
Investigators reported a 90% satisfaction rate at the time of grafting, including among clinicians using Cohealyx for the first time. This high level of acceptance across diverse and complex wound types highlights the product’s consistency and potential to become a new standard in wound bed preparation. Dr Derek Bell, a key opinion leader and Professor of Plastic Surgery at the University of Rochester Medical Center, noted that Cohealyx facilitates earlier grafting by promoting vascularization, which is critical to improving patient outcomes.
The positive interim results come as AVITA Medical continues to build momentum following its recent moves to enhance capital flexibility, including a $200 million shelf registration filed in March 2026 to support growth initiatives and clinical programs like Cohealyx capital flexibility filing. This financial groundwork could enable the company to accelerate commercialisation if the full study data confirms these early findings.
Ongoing Study and Upcoming Data Releases
Cohealyx-I is a prospective, multi-centre, single-arm post-market study assessing safety and performance in patients with full-thickness wounds. The primary endpoint is time to autografting compared to the literature-derived benchmark. Secondary measures include graft take, wound healing, and safety outcomes. Patients will be followed for six months post-grafting to evaluate durability and adverse events.
The full dataset is expected in 2026, with AVITA Medical hosting a key opinion leader webinar on April 16 during the American Burn Association Annual Meeting to discuss the interim findings and clinical implications. This event will feature Dr Bell and other burn care experts, providing a platform for deeper insight into Cohealyx’s potential role in acute wound care.
Positioning Within AVITA Medical’s Wound Care Portfolio
Cohealyx complements AVITA Medical’s RECELL platform, which is FDA-approved for treating thermal burns and trauma wounds. While RECELL harnesses a patient’s own skin cells to create Spray-On Skin™, Cohealyx serves as a dermal matrix to optimise wound beds ahead of grafting. Together, these technologies aim to streamline the wound healing pathway, potentially improving outcomes and reducing treatment times.
As AVITA Medical advances clinical programs for Cohealyx alongside other products like PermeaDerm, the company’s strategic focus on innovation in acute wound care is becoming clearer. The interim results from Cohealyx-I add to a growing body of evidence that could support broader adoption and commercial uptake.
Bottom Line?
The interim data signals Cohealyx’s potential to redefine wound bed preparation, but the full study results in 2026 will be crucial to confirming its clinical and commercial impact.
Questions in the middle?
- Will the full Cohealyx-I data maintain the early statistical superiority over existing dermal matrices?
- How will AVITA Medical leverage its recent capital flexibility to accelerate Cohealyx’s market rollout?
- What competitive responses might emerge from other players in the acute wound care space?